LEADER 04028nam 22004453 450 001 9910796075603321 005 20230629231822.0 010 $a9789280533606$b(electronic bk.) 010 $z9789280533590 035 $a(MiAaPQ)EBC7113890 035 $a(Au-PeEL)EBL7113890 035 $a(CKB)25165210100041 035 $a(OCoLC)1348480949 035 $a(EXLCZ)9925165210100041 100 $a20221019d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCOVID-19-related vaccines and therapeutics $ePreliminary insights on related patenting activity during the pandemic 210 1$aGeneva :$cWorld Intellectual Property Organization,$d2022. 210 4$dİ2022. 215 $a1 online resource (83 pages) 311 08$aPrint version: Staff, World Intellectual Property Organization COVID-19-related vaccines and therapeutics Geneva : World Intellectual Property Organization,c2022 9789280533590 327 $aIntro -- _Hlk93048502 -- Acknowledgements -- Key findings -- Introduction -- Background - biology of COVID-19 -- Overview of patenting activity related to COVID-19 -- Patent filings during 2020-2021 -- Filing and publication of COVID-19-related patent applications over time -- COVID-19-related vaccine and therapeutic patent applicant profiles -- Research collaboration and IP strategies related to technologies important to COVID-19 vaccines and therapeutics -- Disclosure of sequences within patent documents -- COVID-19 vaccines -- Background - vaccine platforms -- Conventional vaccine platforms -- Novel vaccine platforms -- Patent and vaccine distribution by vaccine platform and published applicant location -- Speed of vaccine development -- COVID-19 vaccine patent landscape -- Core vaccine technologies, collaboration and licensing -- Analysis of WHO data on COVID-19 vaccines -- Timelines on key technologies for COVID-19 vaccine development -- Technologies relevant to mRNA vaccine -- Timeline details for adenovirus vaccine development -- Timeline details for vaccine adjuvant development -- COVID-19 therapeutics -- Background -- Analysis of COVID-19 therapeutics-related patent applications by substances type -- Top locations of patent applicants for COVID-19 therapeutics and their filing strategies -- Highlights of patent filings related to COVID-19 therapeutic development -- Patent filings related to development of small-molecule drugs for COVID-19 -- Patent filings related to the development of biologics for COVID-19 -- Patents related to antibodies for COVID-19 treatment -- Peptide and protein therapies -- Nucleic-acid-based therapies -- Aptamer-mediated therapy -- Cell-based therapies -- Other biologic-based therapies -- Analysis of COVID-19 therapeutics in clinical trials. 327 $aAnalysis of COVID-19 therapeutics data in the Milken Institute and Regulatory Affairs Professionals Society (RAPS) tracker data -- Distribution of COVID-19 drug candidates across small molecules and biologics, repurposed drugs and de novo synthesized drugs -- Classification of COVID-19 drug candidates in clinical trials by molecular nature and function -- Feature summary of examples of anti-COVID-19 drug candidates in clinical trials -- Perspectives -- Annex -- Data sources and methods -- Tables of vaccine types and candidates currently in clinical trials -- Examples of partial, early disclosure observed at the Israeli, U.K. and Singapore patent offices -- Glossary -- References -- Further reading. 606 $aCOVID-19 (Disease) 606 $aPatents 606 $aPatents (International law) 615 0$aCOVID-19 (Disease). 615 0$aPatents. 615 0$aPatents (International law). 700 $aStaff$b World Intellectual Property Organization$01484938 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910796075603321 996 $aCOVID-19-related vaccines and therapeutics$93703808 997 $aUNINA